Skip to main content
TXG logo

TXG · 10x Genomics, Inc. · Metrics

Track TXG — free
$51.80 -5.58 (-9.72%) At close · Nov 20 Play latest call Q3 2026 earnings call transcript
Market Cap
$6.81B
Shares
131.53M
Volume · Nov 20 3.23M Avg daily vol (3M) 3.36M

TXG metrics

89 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$51.80
Market cap
$6.81B

Price action

23 metrics
Price change (1W)
-11.0%
Price change (30D)
-25.7%
Price change (3M)
-20.5%
Price change (6M)
+118.8%
Price change (YTD)
+217.6%
Price change (1Y)
+214.7%
Trailing year
Price change (5Y)
-65.5%
52-week high
$97.74
52-week low
$15.46
Change from 52-week high
-47.0%
Change from 52-week low
+235.1%
Annualized volatility
76.9%
Annualized volatility (3M)
87.7%
Implied volatility (30D)
87.2%
IV rank (1Y)
36.3
IV percentile (1Y)
54.9
Beta
2.5
RSI (14D)
35.0
Price vs SMA 50
-28.9%
Price vs SMA 200
+19.1%
Avg volume (3M)
3.36M
Relative volume
1.0
Average dollar volume
$241.07M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
131.53M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
11.0×
reciprocal yield 9.1%
P / book
8.1
reciprocal yield 12.3%
FCF yield
1.4%
TTM · current market cap
Buyback yield
—
P / FCF
72.7
reciprocal yield 1.4%
P / operating cash flow
68.3
reciprocal yield 1.5%
Earnings yield
-1.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
43.2×
reciprocal yield 2.3%
EV / revenue historical average (5Y)
43.2×
reciprocal yield 2.3%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-05

Profitability

9 metrics
Gross margin
71.9%
Operating margin
-11.7%
Trailing 12 months
Net margin
-10.8%
Gross profit (TTM)
$444.65M
Operating profit (TTM)
−$72.20M
Net income (TTM)
−$67.08M
Trailing 12 months
Diluted EPS (TTM)
$-0.52
FCF margin
15.2%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.80
Gross profit per diluted share (TTM)
$3.45
Operating profit per diluted share (TTM)
$-0.56
EBITDA per diluted share (TTM)
$-0.26
Net income per diluted share (TTM)
$-0.52
Operating cash flow per diluted share (TTM)
$0.78
Free cash flow per diluted share (TTM)
$0.73
Capital expenditures per diluted share (TTM)
$0.05
R&D per diluted share (TTM)
$1.73
Stock compensation per diluted share (TTM)
$0.75
Book value per share
$6.24

Growth

11 metrics
Revenue growth YoY
+1.1%
Year over year
Net income growth YoY
—
Revenue (TTM)
$618.58M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+4.2%
Year over year · more shares
Revenue CAGR (3Y)
+7.6%
Revenue CAGR (5Y)
+16.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-8.0%
Return on assets
-6.3%
Debt / equity
—
Current ratio
5.1
EBITDA (TTM)
−$33.01M
Free cash flow (TTM)
$93.77M
Quick ratio
4.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$526.19M
Total assets
$1.06B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$99.70M
Capital expenditures (TTM)
$5.93M
R&D (TTM)
$222.54M
SG&A (TTM)
$297.71M
Stock compensation (TTM)
$96.57M
R&D / revenue
36.0%
Stock compensation / revenue
15.6%

Ownership (13F)

9 metrics
13F filers
494
13F filer change QoQ
+98
Institutional ownership
99.0%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.4%
Holder tenure
17.9
Price vs estimated holder cost
+144.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
15.7%

Short interest

3 metrics
Short interest
9.5%
Latest settlement · 4.1 days to cover
Days to cover
4.1d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$12.61M
Insider-sentiment score
11 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1770787 CUSIP 88025U109 13F (30d) 482 filings 441 filers Visit website Investor relations